• In the past quarter, Knowles reported an exceptional Q1, with revenue rising 15.8% year on year and both sales and non‑GAAP EPS surpassing analyst expectations, while also issuing revenue guidance above consensus for the following quarter.
• This strong quarterly performance and confident outlook stand in contrast to the company’s multi‑year pattern of declining annual sales and below‑sector EPS growth, highlighting a potential turning point in how its operations are scaling against larger competitors.
• We’ll now examine how this earnings beat and upgraded revenue guidance could reshape Knowles’ investment narrative built around medtech, industrial, and defense demand.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Knowles Investment Narrative Recap

To own Knowles, you have to believe its medtech, industrial, and defense exposure can offset years of shrinking sales and subscale operations. The standout Q1 beat and above-consensus Q2 guidance support that view in the near term, but they do not remove the biggest risk today: that product mix, factory inefficiencies, and ramp costs could keep gross margins under pressure even as revenues improve.

The most relevant recent announcement to this quarter’s story is the Q2 2026 outlook, calling for US$152 million to US$162 million in revenue and EPS from continuing operations of US$0.18 to US$0.22. Coming on the heels of a 15.8% year on year Q1 revenue increase and an EPS beat, this guidance reinforces the current growth catalyst around expanding medtech and specialty audio demand, but it still sits against a backdrop of five year annual sales declines of 5.2%.

Yet behind this apparent momentum, investors should also be aware of the risk that Knowles relies heavily on a limited number of customers...

Knowles’ narrative projects $716.9 million revenue and $122.3 million earnings by 2029. This requires 6.5% yearly revenue growth and a $71.4 million earnings increase from $50.9 million today.

Uncover how Knowles' forecasts yield a $28.50 fair value, a 22% downside to its current price.

Exploring Other Perspectives

Before this Q1 surprise, the most pessimistic analysts were still penciling in revenue of about US$657.5 million and earnings of roughly US$158.6 million by 2028, yet they worried that customer concentration and fast moving alternatives could compress valuation multiples; this quarter’s beat may soften that view or reinforce it, depending on how you think those customer and technology risks play out.

Explore 2 other fair value estimates on Knowles - why the stock might be worth as much as 6% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Knowles research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Knowles research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Knowles' overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.